Targeting anandamide metabolism rescues core and associated autistic-like symptoms in rats prenatally exposed to valproic acid.
Autism spectrum disorders (ASD) are characterized by altered sociability, compromised communication and stereotyped/repetitive behaviors, for which no specific treatments are currently available. Prenatal exposure to valproic acid (VPA) is a known, although still underestimated, environmental risk factor for ASD. Altered endocannabinoid activity has been observed in autistic patients, and endocannabinoids are known to modulate behavioral traits that are typically affected in ASD. On this basis, we tested the hypothesis that changes in the endocannabinoid tone contribute to the altered phenotype induced by prenatal VPA exposure in rats, with focus on behavioral features that resemble the core and associated symptoms of ASD. In the course of development, VPA-exposed rats showed early deficits in social communication and discrimination, compromised sociability and social play behavior, stereotypies and increased anxiety, thus providing preclinical proof of the long-lasting deleterious effects induced by prenatal VPA exposure. At the neurochemical level, VPA-exposed rats displayed altered phosphorylation of CB1 cannabinoid receptors in different brain areas, associated with changes in anandamide metabolism from infancy to adulthood. Interestingly, enhancing anandamide signaling through inhibition of its degradation rescued the behavioral deficits displayed by VPA-exposed rats at infancy, adolescence and adulthood. This study therefore shows that abnormalities in anandamide activity may underlie the deleterious impact of environmental risk factors on ASD-relevant behaviors and that the endocannabinoid system may represent a therapeutic target for the core and associated symptoms displayed by autistic patients.
Department of Science, Section of Biomedical Sciences and Technologies, University "Roma Tre", Rome, Italy.
M
M
Servadio
Department of Science, Section of Biomedical Sciences and Technologies, University "Roma Tre", Rome, Italy.
F
F
Melancia
Department of Science, Section of Biomedical Sciences and Technologies, University "Roma Tre", Rome, Italy.
A
A
Manduca
Department of Science, Section of Biomedical Sciences and Technologies, University "Roma Tre", Rome, Italy.
A
A
di Masi
Department of Science, Section of Biomedical Sciences and Technologies, University "Roma Tre", Rome, Italy.
S
S
Schiavi
Department of Science, Section of Biomedical Sciences and Technologies, University "Roma Tre", Rome, Italy.
V
V
Cartocci
Department of Science, Section of Biomedical Sciences and Technologies, University "Roma Tre", Rome, Italy.
V
V
Pallottini
Department of Physiology and Pharmacology, Sapienza University of Rome, Rome, Italy.
P
P
Campolongo
Department of Science, Section of Biomedical Sciences and Technologies, University "Roma Tre", Rome, Italy.
P
P
Ascenzi
Department of Science, Section of Biomedical Sciences and Technologies, University "Roma Tre", Rome, Italy.
V
V
Trezza
Dev Psychobiol. 1999 Apr;34(3):195-204
10204095
J Neurosci. 2000 May 1;20(9):3401-7
10777802
Neurosci Biobehav Rev. 2000 May;24(3):355-64
10781695
Dev Med Child Neurol. 2001 Mar;43(3):202-6
11263692
Nat Med. 2003 Jan;9(1):76-81
12461523
Physiol Rev. 2003 Jul;83(3):1017-66
12843414
Nat Rev Neurosci. 2003 Nov;4(11):873-84
14595399
Neuropsychopharmacology. 2005 Jan;30(1):80-9
15238991
Neuropsychopharmacology. 2006 Jan;31(1):36-46
15920505
Trends Pharmacol Sci. 2006 Mar;27(3):134-40
16476494
Neuropsychopharmacology. 2006 Dec;31(12):2652-9
16541083
Dev Psychobiol. 2006 Apr;48(3):209-19
16568415
J Pharmacol Exp Ther. 2006 Jul;318(1):304-11
16569753
J Autism Dev Disord. 2006 Aug;36(6):779-93
16609825
Eur J Neurosci. 2006 Apr;23(7):1944-8
16623851
J Endocrinol Invest. 2006;29(3 Suppl):27-46
16751707
Pharmacol Rev. 2006 Sep;58(3):389-462
16968947
Behav Brain Res. 2007 Jan 10;176(1):4-20
16971002
J Autism Dev Disord. 2007 May;37(5):877-86
17031447
Psychopharmacology (Berl). 2007 May;192(1):61-70
17279376
Eur J Pharmacol. 2007 Mar 22;559(2-3):180-3
17291487
Neuropsychopharmacology. 2008 Mar;33(4):901-12
17507914
Neuropharmacology. 2008 Jan;54(1):141-50
17709120
Neuropsychopharmacology. 2008 Jun;33(7):1667-79
17957223
J Intellect Disabil. 2007 Dec;11(4):359-70
18029412
Psychopharmacology (Berl). 2008 Apr;197(2):217-27
18058088
Neuropsychopharmacology. 2008 Nov;33(12):2946-56
18305462
J Neurosci. 2008 Mar 5;28(10):2313-9
18322078
J Neurochem. 2008 Jul;106(1):70-82
18331587
Psychoneuroendocrinology. 2008 Jul;33(6):728-40
18396377
Eur Neuropsychopharmacol. 2008 Jul;18(7):519-30
18434104
J Am Acad Child Adolesc Psychiatry. 2008 Aug;47(8):921-9
18645422
PLoS One. 2008 Aug 27;3(8):e3067
18728777
J Pharmacol Exp Ther. 2009 Jan;328(1):343-50
18948500
Psychopharmacology (Berl). 2009 Jul;204(4):607-16
19259645
Genes Brain Behav. 2009 Jul;8(5):519-30
19496827
Neuropsychopharmacology. 2010 Jun;35(7):1500-9
20393458
Autism Res. 2010 Apr;3(2):53-67
20437601
Neuroscience. 2010 Oct 13;170(2):514-22
20603192
Neuropharmacology. 2011 Feb-Mar;60(2-3):235-43
20850463
Biol Psychiatry. 2010 Dec 15;68(12):1100-6
21130222
Behav Brain Res. 2011 Jun 20;220(1):140-5
21295077
J Psychopharmacol. 2012 Jan;26(1):150-63
21693551
Mol Autism. 2011 Jun 29;2(1):10
21714860
Neuroscience. 2012 Mar 1;204:134-44
21827834
PLoS One. 2011;6(10):e26077
22016815
Front Behav Neurosci. 2012 Jan 24;6:2
22291624
PLoS One. 2012;7(5):e37313
22615973
Int J Neuropsychopharmacol. 2013 Apr;16(3):661-76
22647577
Front Pharmacol. 2012 Jun 12;3:110
22701427
Ann Gen Psychiatry. 2012 Jun 25;11(1):16
22731684
Nat Commun. 2012;3:1080
23011134
J Neurosci. 2012 Oct 24;32(43):14899-908
23100412
Nat Med. 2013 May;19(5):603-7
23542787
Cell Tissue Res. 2013 Oct;354(1):81-97
23576070
J Autism Dev Disord. 2013 Nov;43(11):2686-95
23585028
Behav Brain Res. 2013 Jul 15;249:124-32
23643692
Front Behav Neurosci. 2013 Jul 24;7:88
23898245
Lancet. 2014 Mar 8;383(9920):896-910
24074734
Behav Brain Res. 2013 Nov 15;257:253-64
24103642
Neuropsychopharmacology. 2014 Mar;39(4):841-54
24108067
Emerg Health Threats J. 2011 Apr 20;4:7111
24149029
PLoS One. 2014 Jan 13;9(1):e84948
24454768
Science. 2014 Feb 7;343(6171):675-9
24503856
Eur Neuropsychopharmacol. 2014 Aug;24(8):1337-48
24933531
PLoS One. 2014 Aug 18;9(8):e104927
25133713
Front Psychiatry. 2014 Aug 04;5:53
25136320
Neuropharmacology. 1989 Apr;28(4):411-8
2546087
Biol Psychiatry. 2015 Jan 1;77(1):66-74
25483344
PLoS One. 2015 Jan 05;10(1):e0116363
25560049
Eur Neuropsychopharmacol. 2015 Aug;25(8):1362-74
25914159
Behav Pharmacol. 2015 Sep;26(6):522-40
26226143
Behav Pharmacol. 2015 Dec;26(8 Spec No):707-19
26230723
Neurochem Int. 2015 Dec;91:34-45
26498253
Cannabis Cannabinoid Res. 2016 Feb 01;1(1):81-89
28861483
Psychopharmacology (Berl). 1995 Jan;117(2):225-31
7753971
Dev Psychobiol. 1996 May;29(4):353-77
8732808
J Comp Neurol. 1996 Jun 24;370(2):247-61
8808733
Dev Med Child Neurol. 1997 Sep;39(9):632-4
9344057
J Neurosci. 1998 Apr 15;18(8):2834-41
9526000